Your browser doesn't support javascript.
loading
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Oza, Amit M; Matulonis, Ursula A; Alvarez Secord, Angeles; Nemunaitis, John; Roman, Lynda D; Blagden, Sarah P; Banerjee, Susana; McGuire, William P; Ghamande, Sharad; Birrer, Michael J; Fleming, Gini F; Markham, Merry Jennifer; Hirte, Hal W; Provencher, Diane M; Basu, Bristi; Kristeleit, Rebecca; Armstrong, Deborah K; Schwartz, Benjamin; Braly, Patricia; Hall, Geoff D; Nephew, Kenneth P; Jueliger, Simone; Oganesian, Aram; Naim, Sue; Hao, Yong; Keer, Harold; Azab, Mohammad; Matei, Daniela.
Afiliação
  • Oza AM; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto Canada.
  • Matulonis UA; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Alvarez Secord A; Duke Cancer Institute, Durham, North Carolina.
  • Nemunaitis J; University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
  • Roman LD; USC Norris Comprehensive Cancer Center, Los Angeles, California.
  • Blagden SP; University of Oxford, Oxford, United Kingdom.
  • Banerjee S; Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • McGuire WP; Virginia Commonwealth University, Richmond, Virginia.
  • Ghamande S; Augusta University (Georgia Regents University), Augusta, Georgia.
  • Birrer MJ; University of Alabama at Birmingham, Birmingham, Alabama.
  • Fleming GF; The University of Chicago Medicine, Chicago, Illinois.
  • Markham MJ; University of Florida, Gainesville, Florida.
  • Hirte HW; Juravinski Cancer Centre, Hamilton, Canada.
  • Provencher DM; Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Canada.
  • Basu B; Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Kristeleit R; Cancer Institute University College London, UCL, United Kingdom.
  • Armstrong DK; Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland.
  • Schwartz B; Northwell Health Gynecologic Oncology, Bay Shore, New York.
  • Braly P; Women's Cancer Care, Covington, Los Angeles.
  • Hall GD; St James University Hospital, Leeds, United Kingdom.
  • Nephew KP; Indiana University School of Medicine, IU Simon Cancer Center, Bloomington, Indiana.
  • Jueliger S; Astex Pharmaceuticals, Cambridge, United Kingdom.
  • Oganesian A; Astex Pharmaceuticals Inc., Pleasanton, California.
  • Naim S; Astex Pharmaceuticals Inc., Pleasanton, California.
  • Hao Y; Astex Pharmaceuticals Inc., Pleasanton, California.
  • Keer H; Astex Pharmaceuticals Inc., Pleasanton, California.
  • Azab M; Astex Pharmaceuticals Inc., Pleasanton, California.
  • Matei D; Northwestern University Feinberg School of Medicine, Chicago, Illinois. Daniela.matei@northwestern.edu.
Clin Cancer Res ; 26(5): 1009-1016, 2020 03 01.
Article em En | MEDLINE | ID: mdl-31831561
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Medicamentos Antineoplásicos / Epigênese Genética / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Medicamentos Antineoplásicos / Epigênese Genética / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2020 Tipo de documento: Article